NovaBridge Biosciences names Srishti Gupta CEO, replacing Sean Fu
PUBT · 5d ago
Share
Listen to the news
- NovaBridge Biosciences named Srishti Gupta, MD MPP as CEO effective July 1, 2026.
- Gupta also joins the board; she brings more than two decades of leadership in biopharmaceuticals, global health, strategy.
- Outgoing CEO Xi-Yong (Sean) Fu will step down to pursue other opportunities.
- Fu will remain in an advisory role during the transition.
- Gupta will prioritize advancing givastomig toward registration, expanding the Visara ophthalmology franchise, pursuing strategic partnerships.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge Biosciences published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-286812), on June 29, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved